{"organizations": [], "uuid": "9bedc795ded77ffea54f6ac19efeb249ba066177", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-xenon-pharmaceuticals-expects-to-h/brief-xenon-pharmaceuticals-expects-to-have-ongoing-xen1101-phase-1-clinical-trial-completed-by-mid-year-idUSFWN1P30QI", "country": "US", "domain_rank": 408, "title": "BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.027, "site_type": "news", "published": "2018-01-08T21:43:00.000+02:00", "replies_count": 0, "uuid": "9bedc795ded77ffea54f6ac19efeb249ba066177"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-xenon-pharmaceuticals-expects-to-h/brief-xenon-pharmaceuticals-expects-to-have-ongoing-xen1101-phase-1-clinical-trial-completed-by-mid-year-idUSFWN1P30QI", "ord_in_thread": 0, "title": "BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "xenon pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Xenon Pharmaceuticals Inc:\n* XENON PHARMACEUTICALS OUTLINES KEY MILESTONES FOR 2018 * XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR\n* XENON PHARMACEUTICALS INC - IN SECOND HALF OF THIS YEAR, ANTICIPATE HAVING COMPLETED XEN901 PHASE 1 CLINICAL TRIAL\n* XENON PHARMACEUTICALS INC - ANTICIPATE THAT BOTH XEN1101 AND XEN901 COULD BE IN PHASE 2 DEVELOPMENT BY END OF THIS YEAR\n* XENON PHARMACEUTICALS INC - AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $43.7 MILLION\n* XENON PHARMACEUTICALS INC - BASED ON CURRENT ASSUMPTIONS, XENON ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO MID-2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:43:00.000+02:00", "crawled": "2018-01-09T16:50:17.017+02:00", "highlightTitle": ""}